Literature DB >> 20837143

Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway.

Santiago Rodríguez de Córdoba1, Claire L Harris, B Paul Morgan, Oscar Llorca.   

Abstract

Complement is an essential component of innate immunity and a major trigger of inflammatory responses. A critical step in complement activation is the formation of the C3 convertase of the alternative pathway (AP), a labile bimolecular complex formed by activated fragments of the C3 and factor B components that is fundamental to provide exponential amplification of the initial complement trigger. Regulation of the AP C3 convertase is essential to maintain complement homeostasis in plasma and to protect host cells and tissues from damage by complement. During the last decade, several studies have associated genetic variations in components and regulators of the AP C3 convertase with a number of chronic inflammatory diseases and susceptibility to infection. The functional characterization of these protein variants has helped to decipher the critical pathogenic mechanisms involved in some of these complement related disorders. In addition, these functional data together with recent 3D structures of the AP C3 convertase have provided fundamental insights into the assembly, activation and regulation of the AP C3 convertase.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837143     DOI: 10.1016/j.bbadis.2010.09.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  20 in total

1.  Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.

Authors:  Martín Alcorlo; Agustín Tortajada; Santiago Rodríguez de Córdoba; Oscar Llorca
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

2.  Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.

Authors:  Serena Bettoni; Elena Bresin; Giuseppe Remuzzi; Marina Noris; Roberta Donadelli
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

3.  Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.

Authors:  Meike Heurich; Ruben Martínez-Barricarte; Nigel J Francis; Dawn L Roberts; Santiago Rodríguez de Córdoba; B Paul Morgan; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

4.  Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Authors:  Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky
Journal:  Blood Adv       Date:  2021-03-09

5.  Mutational analysis of Kaposica reveals that bridging of MG2 and CUB domains of target protein is crucial for the cofactor activity of RCA proteins.

Authors:  Avneesh Kumar Gautam; Yogesh Panse; Payel Ghosh; Malik Johid Reza; Jayati Mullick; Arvind Sahu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-29       Impact factor: 11.205

6.  Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity.

Authors:  Georgia Sfyroera; Daniel Ricklin; Edimara S Reis; Hui Chen; Emilia L Wu; Yiannis N Kaznessis; Kristina N Ekdahl; Bo Nilsson; John D Lambris
Journal:  J Immunol       Date:  2015-02-23       Impact factor: 5.422

7.  Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy.

Authors:  Martin Alcorlo; Ruben Martínez-Barricarte; Francisco J Fernández; César Rodríguez-Gallego; Adam Round; M Cristina Vega; Claire L Harris; Santiago Rodríguez de Cordoba; Oscar Llorca
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

Review 8.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

Review 9.  Targeting complement-mediated immunoregulation for cancer immunotherapy.

Authors:  Martin Kolev; Maciej M Markiewski
Journal:  Semin Immunol       Date:  2018-02-15       Impact factor: 11.130

10.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.